NCT00002368已完成3 期
An International, Double Blind, Randomized, Phase III Study to Evaluate the Tolerance, Safety, and Effectiveness of Viramune (Nevirapine) in Preventing Clinical AIDS Progression Events or Death When Used in Combination With Lamivudine (3TC) and Stable (>= 4 Weeks) Background Nucleoside Therapy
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 2,000
- 试验地点
- 53
研究概览
简要总结
To evaluate the tolerance, safety, and effectiveness of Viramune in preventing clinical AIDS progression events or death when used in combination with Lamivudine and background nucleoside therapy.
详细描述
Eligible patients will be randomized to treatment with either 1) open-label 3TC twice daily plus Viramune once daily for 2 weeks and then with Viramune twice daily; or 2) open label 3TC twice daily plus Viramune placebo once daily for 2 weeks and then twice daily Viramune. Patients will start Viramune and 3TC on study day 0. Patients will be evaluated for development of AIDS progression events at months 1, 2, 3, and 4, and every 2 months thereafter until 18 months after the last patient is enrolled or 24 months, whichever occurs first.
研究设计
- 研究类型
- Interventional
- 干预模型
- Parallel
- 主要目的
- Treatment
入排标准
- 年龄范围
- 13 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •Documented HIV infection.
- •CD4+ cell count <= 200 cells/mm
- •Life expectancy > 3 months.
- •Written informed consent from parent or guardian for patients < 18 years of age.
- •Willingness and ability to follow protocol requirements.
排除标准
- •Co-existing Condition:
- •Patients with any of the following conditions or symptoms are excluded:
- •Patient is enrolled or plans to enroll during the course of this study in another clinical study of an antiretroviral or other agent used to treat HIV-1 infection.
- •Patients are allowed to participate in opportunistic infection clinical studies if the investigational agent is not contraindicated for the study.
- •Concurrent Medication:
- •Patient is receiving therapy with an antiretroviral agent other than ZDV, d4T, ddI, ddC, or 3TC.
- •Patient is receiving acute therapy for a clinical AIDS progression event such as systemic chemotherapy.
- •Dicumarol, Warfarin and other anticoagulant medications.
- •Tolbutamide.
- •Investigational drugs (unless included in opportunistic infection clinical trial) and all antiretroviral agents (excluding ZDV, ddC, ddI, d4T and 3TC).
- •Neurotoxic drugs.
- •Cimetidine.
- •Erythromycin.
- •Concurrent Treatment:
- •Radiation therapy.
- •Patients with any of the following prior conditions and symptoms are excluded:
- •History of clinically important disease other than HIV-1 infection or related diseases that, in the opinion of the investigator, may put the patient at risk because of participation in this study.
- •Prior Medication:
- •Patient has received prior therapy with Viramune or any other non-nucleoside reverse transcriptase inhibitor.
- •Patient has received any immunosuppressive or cytotoxic drugs or any other experimental agent within 4 weeks prior to study day
- •Patient has received treatment with erythromycin, coumadin/warfarin, phenobarbital, amoxicillin/clavulanic acid, or ticarcillin/clavulanic acid within 2 weeks prior to study day
- •Risk Behavior:
- •Patients who are active chronic alcohol or substance abusers or have an active psychiatric condition sufficient to impair compliance with protocol requirements.
- •Patient must be receiving stable nucleoside therapy with at least one agent for >= 4 weeks prior to study day
- •Zidovudine (ZDV), Zidovudine + Dideoxycytidine (ddC), or Zidovudine + Didanosine (ddI) must be used unless prior intolerance precludes ZDV use. Stable use means no change in dose > 50% for any background nucleoside within four weeks prior to study day
- •If patient is ZDV intolerant, ddC, ddI or D4T monotherapy is allowed.
研究者
研究点 (53)
Loading locations...
相似试验
进行中（未招募）
3 期
Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionPre-Exposure Prophylaxis of HIV InfectionNCT04994509Gilead Sciences5,368
已完成
1 期
A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their InfantsPregnancyHIV InfectionsNCT00000944National Institute of Allergy and Infectious Diseases (NIAID)24
已完成
1 期
Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United StatesHIV InfectionsNCT03382418National Institute of Allergy and Infectious Diseases (NIAID)45
已完成
1 期
Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected AdultsHIV InfectionsNCT01103687National Institute of Allergy and Infectious Diseases (NIAID)24
已完成
1 期
Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive SubjectsAsymptomatic HIV InfectionNCT02456558ApoPharma30